Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.
1. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl{methyl)-1,2-dihydro-3H,8H-2a,5,8triazaacenaphthylene-3,8-dione as shown below:
or a pharmaceutically acceptable salt thereof.
2. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below:
3. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below:
or a pharmaceutically acceptable salt thereof.
4. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below:
5. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below:
or a pharmaceutically acceptable salt thereof.
6. The method according to claim 5 , which comprises administering to the subject (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below:
7. The method according to claim 5 , wherein the pharmaceutically acceptable salt is an acid addition salt formed from an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, fumaric acid, succinic acid, maleic acid, citric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, and tartaric acid.
8. The method according to claim 5 , wherein the pharmaceutically acceptable salt is an acid addition salt formed from methanesulfonic acid.
9. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a mesylate salt of (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2 a, 5,8 a -triazaacenaphthylene-3,8-dione as shown below:
10. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2 a, 5,8 a -triazaacenaphthylene-3,8-dione as shown below:
or a pharmaceutically acceptable salt thereof.
11. The method according to claim 10 , wherein the pharmaceutically acceptable salt is an acid addition salt formed from an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, fumaric acid, succinic acid, maleic acid, citric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, and tartaric acid.
12. The method according to claim 10 , wherein the pharmaceutically acceptable salt is an acid addition salt formed from methanesulfonic acid.